Lung Cancer Screening Market Size, Competitive Strategy, Benchmarking And Forecast 2029

In the ever-evolving realm of business competition, the global market analysis provided by "The Maximize Market Research" acts as a guiding compass, offering a treasure trove of comprehensive insights. By transcending the realm of data and statistics, this analysis unveils the intricate tapestry of competitive landscapes, industry dynamics, and emerging market segments. This wealth of knowledge empowers businesses to forge impactful strategies, foretell market shifts, and cultivate an environment of agility and innovation, paving the way for sustained success in a challenging business ecosystem. By embracing the power of global market analysis, businesses can embark on a transformative journey, unlocking hidden opportunities and positioning themselves at the vanguard of their respective industries.

The lung Cancer Screening Market size was valued at USD 2.36 Billion in 2022 and the total Lung Cancer Screening revenue is expected to grow at a CAGR of 8.32% from 2023 to 2029, reaching nearly USD 4.13 Billion.

Lung Cancer Screening Market Overview:

The purpose of this study is to provide an in-depth analysis of the Lung Cancer Screening market Size by segments, industry, and geography. The study provides detailed information on the major factors influencing the growth of the Lung Cancer Screening industry. The study also includes a thorough examination of the market's value chain.

To get the sample please click here: https://www.maximizemarketresearch.com/request-sample/166924

Market Scope:

The research method used to assess and forecast the Lung Cancer Screening market Growth begins with gathering revenue data from key suppliers using secondary research sources. Vendor offerings are also taken into account while developing market segmentation. Using the bottom-up method, the income of major corporations was utilized to assess the total size of the Lung Cancer Screening market Analysis.

Segmentation:

Based on cancer type, the Non-small Cell Lung Cancer (NSCLC) segment dominated the global lung cancer screening market in 2022, accounting for 78% of the market. At the end of the forecast period, this sector is predicted to maintain its dominance with the greatest market share of 85%. The most frequent type of cancer is non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases. NSCLC subtypes, on the other hand, include large cell carcinoma, adenocarcinoma, squamous cell carcinoma, and other less prevalent kinds of NSCLC. Increased screening awareness in established and developing nations, as well as an increase in NSCLC incidence globally, will drive segment growth throughout the projection period.

As a result, the category is predicted to increase at an 8.24% CAGR during the forecast period. According to the American Cancer Society, non-small cell lung cancer accounts for around 84% of all lung cancers, while small cell lung cancer accounts for 13%. Meanwhile, the five-year survival rate for NSCLC is 24%, compared to 6% for SCLC, according to Cancer.Net.

Global Lung Cancer Screening Market, by Cancer Type (2022-2029)
• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer
Global Lung Cancer Screening Market, by Diagnosis Type (2022-2029)
• Low Dose Spiral CT Scan
• Chest X-ray
Global Lung Cancer Screening Market, by Age Group (2022-2029)
• 50 and Older
• Below 50
Global Lung Cancer Screening Market, by End-user (2022-2029)
• Hospitals & Clinics
• Diagnostic Centres
• Other

Key Players: the key players are:

1. GE Healthcare (United States)
2. PenRad Technologies, Inc. (United States)
3. NanoString, Myriad Genetics Inc. (United States)
4. OncoCyte (United States)
5. Biodesix (United States)
6. Broncus (United States)
7. Abbott (United States)
8. Illumina, Inc., (United States)
9. Thermo Fischer Scientific (United States)
10. Medtronic (United States)
11. Nuance Communications, Inc. (United States)
12. Riverain Tech (United States)
13. 20/20 Gene Systems (United States)
14. Danaher Corporation (United States)
15. NeoGenomics (United States)
16. Eon Health (United States)
17. Siemens Healthineers AG (Germany‎)
18. Agilent Technologies, Inc., AstraZeneca (United Kingdom)
19. Insight Genetics (United Kingdom)
20. Inivata (United Kingdom)
21. Oncimmune (United Kingdom)
22. Koninklijke Philips N.V. (The Netherlands‎)
23. QIAGEN (The Netherlands)
24. Quest Diagnostics Incorporated (The Netherlands)
25. F. Hoffmann-La Roche Ltd. (Switzerland)
26. Janssen Pharmaceuticals, Inc. (Belgium)
27. Sanofi, (France)
28. Canon Medical Systems Corporation (Japan)
29. FUJIFILM Holdings Corporation (Japan)
30. VisionGate (India)
31. Integrated Diagnostics (India)
32. Volpara Solutions Limited. (New Zealand)

Regional Analysis:

North America, Europe, Asia-Pacific, the Middle East and Africa, and South America each have their own market share data. Maximize analysts assess competitive strengths and conduct competitive analysis on each rival separately.

COVID-19 Impact Analysis on Lung Cancer Screening Market:

The detailed review of COVID-19 impact on the Lung Cancer Screening market based on import, suppliers, ket players have also been included in the Lung Cancer Screening market report.

The following are the key questions addressed in the Lung Cancer Screening Market Report:

• Which segment had the largest share in the Lung Cancer Screening market?
• How is the competitive landscape of the Lung Cancer Screening market?
• Which are the key factors impacting the Lung Cancer Screening market growth?
• Which region has the maximum share in the Lung Cancer Screening market?
• What will be the CAGR of the Lung Cancer Screening market during the forecast period (2023-2029)?

Browse the Summary of the Research Report to Gain More Insights into the Market Analysis: https://www.maximizemarketresearch.com/market-report/lung-cancer-screening-market/166924/

About Maximize Market Research:

Maximise Market Research is a market research and consulting firm with professionals from various industries. Medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology, and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems are among the industries we cover. We offer market-verified industry estimates, technical trend analysis, critical market research, strategic counsel, competitive analysis, production and demand analysis, and client impact studies, to name a few.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

sales@maximizemarketresearch.com

+91 96071 95908, +91 9607365656